Gianluca Iacobellis is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1450 NW 10th Ave
Miami, FL 331361011
Telephone
305-243-3636Registry record last updated 25 Sept 2014.
Clinical trials
- Effects of DPP4 Inhibition on COVID-19
Sponsor: University of Miami
- Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
Sponsor: University of Miami
- Liraglutide Effects on Epicardial Fat Inflammatory Genes
Sponsor: University of Miami
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20252 payments
- Janssen Biotech, Inc.Program year20221 payment
- Lilly USA, LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
86.9%GLP-1 receptor agonist28.1%Ozempic36%Mounjaro36%Trulicity22%Rybelsus5%Victoza 3-Pak1%Part D<11 patientsInsulin Analog24%Tresiba Flextouch U-10025%Lantus Solostar18%Novolog Flexpen15%Humalog Kwikpen U-10010%Tresiba Flextouch U-2006%Levemir Flexpen4%Fiasp Flextouch4%Basaglar Kwikpen U-1004%Lantus3%Insulin Lispro Kwikpen U-1003%Novolog3%Insulin Lispro2%Lyumjev Kwikpen U-1002%Toujeo Solostar2%Part D<11 patients+ 8 more classes in this area
Cardiovascular
7.7%Statin4.7%Rosuvastatin Calcium50%Atorvastatin Calcium50%Part D≥33 patientsCalcium channel blocker0.8%Amlodipine Besylate100%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
4.5%l-Thyroxine4.5%Levothyroxine Sodium92%Synthroid8%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”